https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-custom-pa-grade-led-heat-sink-1.pdf
https://www.avient.com/sites/default/files/2023-07/Avient-2022-Sustainability-Report.pdf
Jeddah, Saudi Arabia 1.
HAPs: 6.96 MT Metrics—Planet Metrics Page 86 Energy Management (1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable, (4) total self-generated energy RT-CH-130a.1 1.
Workforce Health & Safety (1) Total recordable incident rate (TRIR) and (2) fatality rate for (a) direct employees and (b) contract employees RT-CH-320a.1 1.
https://www.avient.com/sites/default/files/2024-08/Avient-2023-Sustainability-Report_6.pdf
Jurong, Singapore 1.
HAPs: 6.77 MT Metrics—Planet Metrics Page 77 Energy Management (1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable, (4) total self-generated energy RT-CH-130a.1 1.
Workforce Health & Safety (1) Total recordable incident rate (TRIR) and (2) fatality rate for (a) direct employees and (b) contract employees RT-CH-320a.1 1.
https://www.avient.com/sites/default/files/2023-03/2023 Avient Bookmarked Proxy Statement - FINAL.pdf
This information is as of March 1, 2023.
aa) “Predecessor Plans” means the PolyOne Corporation 2010 Equity and Performance Incentive Plan and the PolyOne Corporation 2017 Equity and Incentive Compensation Plan, in each case including as may be (or may have been) amended or amended and restated from time to time.
The PolyOne Corporation 2020 Equity and Incentive Compensation Plan was effective as of the Effective Date.
https://www.avient.com/investor-center/events/polyone-corporation-2014-goldman-sachs-us-emerging/smid-cap-growth-conference
https://www.avient.com/investor-center/events/polyone-corporation-jefferies-group-inc-global-industrial-and-aerospace-defense-conference
https://www.avient.com/investor-center/events/q3-2012-polyone-corporation-earnings-and-discuss-agreement-acquire-spartech-conference-call
https://www.avient.com/investor-center/events/polyone-corporation-credit-suisse-22nd-annual-global-chemical-and-ag-science-conference
https://www.avient.com/investor-center/events/polyone-corporation-celebrates-10-years-trading-nysechairman-president-and-ceo-stephen-d-newlin-rings-opening-bell
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-ophthalmic-closures-application-bulletin-cn.pdf
MEVOPUR Colors for Ophthalmic Closures Application Bulletin_CN8.18-1 * 可根据要求提供FDA/EU合规信息 应用公告 用于眼科药物容器盖的 着色剂MEVOPUR™ 用于眼部(眼科)用药物容器盖的MEVOPUR标 准母粒系列产品符合美国眼科学会(AAO)的颜 色标准。
法规支持 经过预测试的原材料: - ISO 10993-1 - USP 第、章(VI类) - USP (指南),6.2.3 可萃取元素; USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃(如适用) FDA发布的注册药品管理档案(III类)和/或医 疗器械管理档案 食品接触符合FDA/EU*要求 • • • 主要特性 在三个通过ISO 13485认证的医疗生产线生产 全球统一的配方,提供全球一致性和供应链保 障 变更控制记录的不限于CAS编号级别,降低变 更风险 不含动物源性物质和邻苯二甲酸盐 标准母粒在PE载体中提供,可根据要求在PP 中提供 可以采用针对应用选择的特定树脂提供预着色 配方 • • • • • 药物类型 颜色说明 潘通色号参考 埃万特产品代码 (PE基) 肾上腺素能激动剂组合 浅绿色 373 C PE6M176349 肾上腺素能激动剂 紫色 2583 C PE4M176057 抗感染药 棕褐色 467 C PE8M176130 非甾体类抗炎药 灰色 冷灰色 4 C PE7M176184 甾体类抗炎药 粉色 197 C PE3M176237 免疫调节剂类抗炎药 橄榄绿 5763 C 按要求提供 β-受体阻滞剂 黄色 黄色 C PE1M176160 β-受体阻滞剂组合 深蓝色 281 C PE5M176272 碳酸酐酶抑制剂 橘黄色 1585 C PE2M176089 细胞毒素 黑色 6 C PL9M176008 缩瞳剂 深绿色 348 C PE6M176267 散瞳剂和睫状肌麻痹剂 红色 1797 C PE3M176236 前列腺素类似物 绿松石 326 C PE5M176273 适用医疗保健使用限制—见下文。
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用: (1) 接触人体组织或体液长达30天或更长时间; (2)“整形”(整容或重建)手术; (3) 生殖植入物或任何节育器械;或者 (4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。